Ultragenyx Pharmaceutical | RARE - Vertriebs- Und Verwaltungskosten

Aktienkurs
23.30
Täglich Wechseln
-0.61 -2.55%
Monatlich
4.91%
Jährlich
-31.75%
Q2 Prognose
22.66




Vertriebs- Und Verwaltungskosten Veränderung Datum
Acadia Pharmaceuticals USD 146.73M 21.82M 2025-12
Agios Pharmaceuticals USD 42.97M 1.7M 2025-12
Alnylam Pharmaceuticals USD 285.06M 22.47M 2025-12
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
BioMarin Pharmaceutical USD 322.21M 98.79M 2025-12
Esperion Therapeutics USD 39.42M 456K 2025-12
Immunic USD -0.24 0.03 2024-09
Insmed USD 212.48M 26.11M 2025-12
Ionis Pharmaceuticals USD 130M 43.43M 2025-12
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
Kyowa Hakko Kirin JPY 43.89B 5.17B 2025-12
MacroGenics USD 7.94M 1.96M 2025-12
Moderna USD 308M 40M 2025-12
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
PTC Therapeutics USD 87.2M 3.15M 2025-12
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Sarepta Therapeutics USD 105.38M 28.27M 2025-12
Ultragenyx Pharmaceutical USD 89M 2.38M 2025-12
Vertex Pharmaceuticals USD 487M 41.9M 2025-12
Xoma USD 11M 2.54M 2024-06